Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection

NCT01032408 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

154

Enrollment

INDUSTRY

Sponsor class

Conditions

H1N1 Influenza Virus
Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Interventions

BIOLOGICAL: Focetria®
BIOLOGICAL: Begrivac®

Sponsor

Chiltern Pesquisa Clinica Ltda